Research programme: anticancer monoclonal antibodies - MabVax/MSKCC
Alternative Names: 1B7; 1B7/31F; Anti-GD2 antibodies - MabVax Therapeutics; HuMab-1B7; HuMab-31F9; HuMab-Tn; r5B1Latest Information Update: 28 Nov 2019
At a glance
- Originator MabVax Therapeutics
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; GD2 ganglioside inhibitors; Tumour associated carbohydrate antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 09 May 2019 BioNTech acquires pre-clinical antibody assets from MabVax Therapeutics
- 09 Jul 2018 Monoclonal antibodies targetting glycans (Thomsen-nouveau (Tn) and the sialyl Tn (sTn) carbohydrate antigens) licensed to Boehringer ingelheim